GE HealthCare Technologies Inc. (NASDAQ:GEHC) Position Increased by Versant Capital Management Inc

Versant Capital Management Inc boosted its stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 19.0% in the fourth quarter, HoldingsChannel reports. The firm owned 6,125 shares of the company’s stock after purchasing an additional 980 shares during the quarter. Versant Capital Management Inc’s holdings in GE HealthCare Technologies were worth $479,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the company. Commonwealth Equity Services LLC increased its stake in GE HealthCare Technologies by 0.9% in the 2nd quarter. Commonwealth Equity Services LLC now owns 162,624 shares of the company’s stock worth $12,672,000 after purchasing an additional 1,511 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in shares of GE HealthCare Technologies by 8.7% in the second quarter. Farther Finance Advisors LLC now owns 4,077 shares of the company’s stock valued at $311,000 after buying an additional 327 shares during the period. Rhumbline Advisers lifted its position in GE HealthCare Technologies by 4.5% in the second quarter. Rhumbline Advisers now owns 802,154 shares of the company’s stock worth $62,504,000 after purchasing an additional 34,307 shares during the period. Oregon Public Employees Retirement Fund boosted its position in shares of GE HealthCare Technologies by 0.5% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 36,482 shares of the company’s stock valued at $2,843,000 after acquiring an additional 176 shares in the last quarter. Finally, Foundations Investment Advisors LLC grew its stake in shares of GE HealthCare Technologies by 9.8% in the 2nd quarter. Foundations Investment Advisors LLC now owns 3,087 shares of the company’s stock valued at $241,000 after purchasing an additional 276 shares during the period. Institutional investors own 82.06% of the company’s stock.

GE HealthCare Technologies Stock Performance

Shares of GEHC opened at $78.38 on Friday. The stock has a 50-day moving average of $82.61 and a 200-day moving average of $83.88. GE HealthCare Technologies Inc. has a one year low of $71.31 and a one year high of $94.55. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.23 and a quick ratio of 0.98. The company has a market cap of $35.81 billion, a PE ratio of 21.53, a P/E/G ratio of 2.96 and a beta of 1.07.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.14 EPS for the quarter, beating the consensus estimate of $1.06 by $0.08. The firm had revenue of $4.86 billion during the quarter, compared to analyst estimates of $4.87 billion. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The company’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter last year, the business posted $0.99 EPS. On average, equities research analysts predict that GE HealthCare Technologies Inc. will post 4.3 EPS for the current fiscal year.

GE HealthCare Technologies Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Tuesday, January 14th will be issued a dividend of $0.035 per share. This is a boost from GE HealthCare Technologies’s previous quarterly dividend of $0.03. The ex-dividend date of this dividend is Tuesday, January 14th. This represents a $0.14 dividend on an annualized basis and a yield of 0.18%. GE HealthCare Technologies’s payout ratio is presently 3.85%.

Insider Activity at GE HealthCare Technologies

In related news, CEO Roland Rott sold 3,577 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total value of $309,338.96. Following the transaction, the chief executive officer now owns 24,298 shares of the company’s stock, valued at $2,101,291.04. This represents a 12.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.27% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on GEHC. Evercore ISI raised their price objective on shares of GE HealthCare Technologies from $98.00 to $102.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. JPMorgan Chase & Co. assumed coverage on GE HealthCare Technologies in a report on Monday, September 9th. They set a “neutral” rating and a $90.00 price objective for the company. UBS Group lowered GE HealthCare Technologies from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $84.00 to $74.00 in a research report on Thursday, September 26th. Stifel Nicolaus lifted their price objective on shares of GE HealthCare Technologies from $100.00 to $102.00 and gave the stock a “buy” rating in a research note on Monday, September 30th. Finally, BTIG Research raised GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a research note on Wednesday, September 18th. One research analyst has rated the stock with a sell rating, four have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, GE HealthCare Technologies has a consensus rating of “Moderate Buy” and a consensus price target of $95.46.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.